Lapatinib and trastuzumab are more sensitive to ErbB2-positive breast cancer cells when the laminin-binding integrins (α6β4 integrin and α3β1 integrin) are inhibited in normal culture conditions [156]. Here, ERBB2 is linked to breast cancer.